Cargando…
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease
BACKGROUND AND PURPOSE: Apremilast is an oral nonbiologic medication approved for the treatment of adult patients with active psoriatic arthritis and for patients with moderate to severe plaque psoriasis. This article summarizes the efficacy and safety of apremilast and provides characterization of...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5157723/ https://www.ncbi.nlm.nih.gov/pubmed/27869356 http://dx.doi.org/10.1002/2327-6924.12428 |
_version_ | 1782481504192954368 |
---|---|
author | Young, Melodie Roebuck, Heather L. |
author_facet | Young, Melodie Roebuck, Heather L. |
author_sort | Young, Melodie |
collection | PubMed |
description | BACKGROUND AND PURPOSE: Apremilast is an oral nonbiologic medication approved for the treatment of adult patients with active psoriatic arthritis and for patients with moderate to severe plaque psoriasis. This article summarizes the efficacy and safety of apremilast and provides characterization of the novel medication with clinical perspectives to successfully incorporate this therapy into practice for appropriate patients. DATA SOURCES: A review and synthesis of the results from the ESTEEM (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis) phase 3 clinical studies evaluating the efficacy, safety, and tolerability of apremilast for the treatment of moderate to severe plaque psoriasis was conducted. CONCLUSIONS: Results from the ESTEEM clinical trial program demonstrate that apremilast significantly reduces the severity of moderate to severe plaque psoriasis, has an acceptable safety profile, and is generally well tolerated. IMPLICATIONS FOR PRACTICE: The novel mechanism of action, convenience of oral administration, and acceptable side effect profile make this medication an attractive choice for clinicians treating patients with plaque psoriasis. |
format | Online Article Text |
id | pubmed-5157723 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-51577232016-12-30 Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease Young, Melodie Roebuck, Heather L. J Am Assoc Nurse Pract Supplement Article BACKGROUND AND PURPOSE: Apremilast is an oral nonbiologic medication approved for the treatment of adult patients with active psoriatic arthritis and for patients with moderate to severe plaque psoriasis. This article summarizes the efficacy and safety of apremilast and provides characterization of the novel medication with clinical perspectives to successfully incorporate this therapy into practice for appropriate patients. DATA SOURCES: A review and synthesis of the results from the ESTEEM (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis) phase 3 clinical studies evaluating the efficacy, safety, and tolerability of apremilast for the treatment of moderate to severe plaque psoriasis was conducted. CONCLUSIONS: Results from the ESTEEM clinical trial program demonstrate that apremilast significantly reduces the severity of moderate to severe plaque psoriasis, has an acceptable safety profile, and is generally well tolerated. IMPLICATIONS FOR PRACTICE: The novel mechanism of action, convenience of oral administration, and acceptable side effect profile make this medication an attractive choice for clinicians treating patients with plaque psoriasis. John Wiley and Sons Inc. 2016-11-21 2016-12 /pmc/articles/PMC5157723/ /pubmed/27869356 http://dx.doi.org/10.1002/2327-6924.12428 Text en ©2016 The Authors. Journal of the American Association of Nurse Practitioners published by Wiley Periodicals, Inc. on behalf of American Association of Nurse Practitioners. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Supplement Article Young, Melodie Roebuck, Heather L. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease |
title | Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease |
title_full | Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease |
title_fullStr | Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease |
title_full_unstemmed | Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease |
title_short | Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease |
title_sort | apremilast, an oral phosphodiesterase 4 (pde4) inhibitor: a novel treatment option for nurse practitioners treating patients with psoriatic disease |
topic | Supplement Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5157723/ https://www.ncbi.nlm.nih.gov/pubmed/27869356 http://dx.doi.org/10.1002/2327-6924.12428 |
work_keys_str_mv | AT youngmelodie apremilastanoralphosphodiesterase4pde4inhibitoranoveltreatmentoptionfornursepractitionerstreatingpatientswithpsoriaticdisease AT roebuckheatherl apremilastanoralphosphodiesterase4pde4inhibitoranoveltreatmentoptionfornursepractitionerstreatingpatientswithpsoriaticdisease |